AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
$430M
Attovia TherapeuticsOllin Biosciences
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsOllin Biosciences
Biotech
Sector
Biotech
2023
Founded
2023
San Carlos, CA
HQ
Chicago, Illinois
Public (ATTO)
Status
Private
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Ollin Biosciences.